In recent years, GLP-1 RA has gradually been favored by clinicians and patients, and GLP-1 RA represented by semaglutide can effectively reduce glycemia and weight in patients with T2DM (49), with good clinical efficacy. This evidence concerns the gene GCG and type 2 diabetes mellitus.